Cover Image

Guidance for industry : Q4B evaluation and recommendation of pharmocopoeial texts for use in the ICH regions : annex 3 test for particulate contamination, subdivisible particles general chapter.

Bibliographic Details
Corporate Authors:	Center for Drug Evaluation and Research (U.S.), Center for Biologics Evaluation and Research (U.S.), International Conference on Harmonisation
Format:	Government Document Conference Proceeding eBook
Language:	English
Published:	Silver Spring, MD : Rockville, MD : U.S. Dept. of Health and Human Services, Food and Drug Administration, Center for Drug Evaluation and Research (CDER) ; Center for Biologics Evaluation and Research (CBER), [2009]
Subjects:	Drugs > Microbiology > Testing.
Online Access:	https://purl.fdlp.gov/GPO/LPS110544

Similar Items

Q4B, annex 3, evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on test for particulate contamination, sub-visible particles /
Published: (2007)

Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on Sterility Test General Chapter.

Guidance for industry : Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH region.
Published: (2009)

Guidance for industry : Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH region.
Published: (2009)

Guidance for industry : Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH region.
Published: (2009)

Guidance for industry : Q1E evaluation of stability data.
Published: (2004)

Guidance for industry : Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH region.
Published: (2009)

Guidance for industry : Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH region.
Published: (2009)

Guidance for industry : S1B testing for carcinogenicity of pharmaceuticals.
Published: (1997)

Guidance for industry : Q1B photostability testing of new drug substances and products.
Published: (1996)

Guidance for industry : Q1A(R2) stability testing of new drug substances and products.
Published: (2003)

Guidance for industry : Q1D bracketing and matrixing designs for stability testing of new drug substances and products.
Published: (2003)

Evaluation and recommendation of pharmacopoeial texts for use in the ICH regions on Dissolution Test General Chapter.

Guidance for industry : Q3C impurities, residual solvents.
Published: (1997)

Guidance for industry : stability testing, photostability testing of new veterinary drug substances and medicinal products.
Published: (1999)

Guidance for industry : validation of growth-based rapid microbiological methods for sterility testing of cellular and gene therapy products.
Published: (2008)

Guidance for industry : class II special controls guidance document : in vitro HIV drug resistance genotype assay.
Published: (2007)

Guidance for industry : S2B genotoxicity, a standard battery for genotoxicity testing of pharmaceuticals.
Published: (1997)

Guidance for industry : photosafety testing.
Published: (2003)

Guidance for industry : S6 preclinical safety evaluation of biotechnology-derived pharmaceuticals.
Published: (1997)

Guidance for industry : stability testing of new veterinary dosage forms.
Published: (1999)

Guidance for industry : drug-induced liver injury, premarketing clinical evaluation.
Published: (2007)

Guidance for industry : nonclinical safety evaluation of drug or biologic combinations.
Published: (2006)

Guidance for industry : CGMP for phase 1 investigational drugs.
Published: (2008)

Guidance for industry : investigating out-of-specification test results (OOS) for pharmaceutical production.
Published: (2006)

Guidance for industry : S7A safety pharmacology studies for human pharmaceuticals.
Published: (2001)

Guidance for industry : S7B nonclinical evaluation of the potential for delayed ventricular repolarization (QT Interval Prolongation) by human pharmaceuticals.
Published: (2005)

Guidance for industry : E14 clinical evaluation of QT/QTc interval prolongation and proarrhythmic potential for non-antiarrhythmic drugs.
Published: (2005)

Guidance for industry : S8 immunotoxicity studies for human pharmaceuticals.
Published: (2006)

Guidance for industry : estimating the maximum safe starting dose in initial clinical trials for therapeutics in adult healthy volunteers.
Published: (2005)

Q4B evaluation and recommendation of pharmacopoeial texts for use in the ICH regions : annex 5, disintegration test general chapter.
Published: (2008)

Guidance for industry : tropical disease priority review vouchers.
Published: (2008)

Guidance for industry : studies to evaluate the safety of residues of veterinary drugs in human food, carcinogenicity testing.
Published: (2006)

Guidance for industry : nonclinical safety evaluation of pediatric drug products.
Published: (2006)

Guidance for industry : stability testing of new biotechnological/biological veterinary medicinal products.
Published: (2001)

Guidance for industry : M3 nonclinical safety studies for the conduct of human clinical trials for pharmaceuticals.
Published: (1997)

Guidance for industry : S1C(R2) dose selection for carcinogenicity studies.
Published: (2008)

Guidance for industry : process validation, general principles and practices.
Published: (2008)

Guidance for industry : handling and retention of BA and BE testing samples.
Published: (2004)

Guidance for industry : drug-induced liver injury, premarketing clinical evaluation.
Published: (2009)